Navigation Links
Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
Date:1/5/2016

RICHMOND, Calif., Jan. 5, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the Company's clinical and preclinical ZFP Therapeutic® programs and upcoming milestones, as well as an overview of Sangamo's business strategy at 9:30 am PT on Tuesday, January 12th, at the 34th Annual J.P. Morgan Healthcare Conference. The conference will be held from January 11-14 in San Francisco, CA.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations.  The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP™) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders.  In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

 

 

 


 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
3. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
5. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
6. Sangamo BioSciences Proposes Public Offering Of Common Stock
7. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
8. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
9. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
10. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
11. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... September 06, 2018 , ... The Discovery on Target (DOT) ... “The industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening ... these emerging targets in a quest to find new treatments for disease. , ...
(Date:9/1/2018)... ... August 31, 2018 , ... Rudina Thanasi, a scientifically validated ... biofield energy treated nutraceutical supplement used in combating inflammation and autoimmune disorders. ... as well as, organ-specific inflammation. The reported data is as follows: , ...
(Date:8/29/2018)... ... , ... Cognition Corporation ®, a software company specializing in medical device ... , Ryan Ward, Director of Engineering at Zimmer Biomet, has been announced as ... manager with Zimmer Biomet for almost 15 years, Mr. Ward will focus his talk ...
(Date:8/29/2018)... ... August 28, 2018 , ... USDM Life Sciences , ... sciences and healthcare industries, announces that Manu Vohra will deliver a presentation at the ... “How to Implement Box for GxP in 30 Days” , When: Thursday, August ...
Breaking Biology Technology:
(Date:9/15/2018)... , ... September 14, 2018 , ... ... Diseases." This campaign will showcase the innovative work being done within rare diseases ... future therapies for those living with rare diseases. , The ...
(Date:9/7/2018)... STATION, Texas (PRWEB) , ... September 05, 2018 ... ... Turnkey Facility Platform for a mAb manufacturing facility late last year, IPS-Integrated Project ... PODs for the manufacturing of autologous cell therapies. The iCON solution provides a ...
(Date:8/31/2018)... ... August 30, 2018 , ... CallTower is ... has more than 20-years of telecommunications experience and over ten years in executive leadership. ... was acquired by CallTower in early 2018. , In this new role, ...
Breaking Biology News(10 mins):